Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs
JA Hamilton - The Lancet, 1993 - Elsevier
JA Hamilton
The Lancet, 1993•ElsevierThe pathogenesis of rheumatoid arthritis and the mode of action of anti-rheumatic drugs are
unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating
factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis
and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic
drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs
would result in fewer inflammatory cells in the inflamed joints.
unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating
factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis
and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic
drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs
would result in fewer inflammatory cells in the inflamed joints.
Abstract
The pathogenesis of rheumatoid arthritis and the mode of action of anti-rheumatic drugs are unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs would result in fewer inflammatory cells in the inflamed joints.
Elsevier
